Infliximab (Remicade) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Mucocutaneous lymph node syndrome
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Apr 2018 Results of development of population pharmacokinetic model by using data from this study and other published in the Clinical Pharmacokinetics.
- 14 Apr 2014 Results published in the Lancet (online).